Macular Degeneration Treatment Market 2028 By Disease Indication, Drug Class, End User | The Insight Partners

    Macular Degeneration Treatment Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Disease Indication (Dry Age-related macular degeneration treatment, Wet age-related macular de-generation treatment, Others); Drug Class (Anti-Vascular endothelial growth factor, Others); End User (Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals)

    Report Code: TIPRE00004433 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

    MARKET INTRODUCTION


    Macular Degeneration is a medical condition that may result in blurred or no vision in the center of the visual field. There may be no symptoms at times at the beginning of macular degeneration, but eventually some people experience a gradual worsening of vision that may affect both or one eye.

    MARKET DYNAMICS


    The Macular Degeneration Treatment Market is anticipated to grow in the forecast period owing to driving factors such as increasing population of geriatric patients, rising patient population suffering from Macular Degeneration, growing awareness about drugs for treating AMD, introduction on new therapies, improving healthcare as well as healthcare infrastructure, and increase in prevalence and incidence of retinal disorders. Nevertheless, continuous pressure from some key players in binding the usage of different drugs for wet AMD and intrusive administration methods is expected to restrict the market growth during the forecast period.

    MARKET SCOPE


    The "Global Macular Degeneration Treatment Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Macular Degeneration Treatment Market with detailed market segmentation by Disease Indication, Drug Class, End User and geography. The global Macular Degeneration Treatment Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Macular Degeneration Treatment Market players and offers key trends and opportunities in the market.

    MARKET SEGMENTATION


    The global Macular Degeneration Treatment Market is segmented on the basis of Disease Indication, Drug Class and End User. Based on Disease Indication the market is segmented into Dry Age-related macular degeneration treatment, Wet age-related macular de-generation treatment and Others. Based on Drug Class the market is segmented into Anti-Vascular endothelial growth factor and Others. Based on End User the market is segmented into Ambulatory Surgical Centers, Ophthalmic Clinics and Hospitals.

    Get more information on this report :

    REGIONAL FRAMEWORK


    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Macular Degeneration Treatment Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Macular Degeneration Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

    The report analyzes factors affecting Macular Degeneration Treatment Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Macular Degeneration Treatment Market in these regions.

    Get more information on this report :

    MARKET PLAYERS


    The reports cover key developments in the Macular Degeneration Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Macular Degeneration Treatment Market are anticipated to lucrative growth opportunities in the future with the rising demand for Macular Degeneration Treatment Market in the global market. Below mentioned is the list of few companies engaged in the Macular Degeneration Treatment Market.

    The report also includes the profiles of key Macular Degeneration Treatment Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development In Past Five Years.
    • GlaxoSmithKline plc
    • Novartis AG
    • Bayer AG
    • Neurotech Pharmaceuticals, Inc
    • Ophthotech Corporation
    • F. Hoffmann-La Roche Ltd
    • StemCells Inc
    • Pfizer, Inc
    • Sanofi
    • Santen Pharmaceuticals
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

    Get more information on this report :

    TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Macular Degeneration Treatment Market - By Disease Indication
    1.3.2 Macular Degeneration Treatment Market - By Drug Class
    1.3.3 Macular Degeneration Treatment Market - By End User
    1.3.4 Macular Degeneration Treatment Market - By Region
    1.3.4.1 By Country
    2. KEY TAKEWAYS
    3. RESEARCH METHODOLOGY
    4. MACULAR DEGENERATION TREATMENT MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PEST ANALYSIS
    4.2.1 North America - Pest Analysis
    4.2.2 Europe - Pest Analysis
    4.2.3 Asia-Pacific - Pest Analysis
    4.2.4 Middle East and Africa - Pest Analysis
    4.2.5 South and Central America - Pest Analysis
    4.3. EXPERT OPINIONS
    5. MACULAR DEGENERATION TREATMENT MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
    6. MACULAR DEGENERATION TREATMENT MARKET - GLOBAL MARKET ANALYSIS
    6.1. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET OVERVIEW
    6.2. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE
    7. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
    7.1. OVERVIEW
    7.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
    7.3. DRY AGE-RELATED MACULAR DEGENERATION TREATMENT
    7.3.1. Overview
    7.3.2. Dry Age-related macular degeneration treatment Market Forecast and Analysis
    7.4. WET AGE-RELATED MACULAR DE-GENERATION TREATMENT
    7.4.1. Overview
    7.4.2. Wet age-related macular de-generation treatment Market Forecast and Analysis
    7.5. OTHERS
    7.5.1. Overview
    7.5.2. Others Market Forecast and Analysis
    8. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
    8.1. OVERVIEW
    8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
    8.3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
    8.3.1. Overview
    8.3.2. Anti-Vascular endothelial growth factor Market Forecast and Analysis
    8.4. OTHERS
    8.4.1. Overview
    8.4.2. Others Market Forecast and Analysis
    9. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER
    9.1. OVERVIEW
    9.2. END USER MARKET FORECASTS AND ANALYSIS
    9.3. AMBULATORY SURGICAL CENTERS
    9.3.1. Overview
    9.3.2. Ambulatory Surgical Centers Market Forecast and Analysis
    9.4. OPHTHALMIC CLINICS
    9.4.1. Overview
    9.4.2. Ophthalmic Clinics Market Forecast and Analysis
    9.5. HOSPITALS.
    9.5.1. Overview
    9.5.2. Hospitals. Market Forecast and Analysis
    10. MACULAR DEGENERATION TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    10.1. NORTH AMERICA
    10.1.1 North America Macular Degeneration Treatment Market Overview
    10.1.2 North America Macular Degeneration Treatment Market Forecasts and Analysis
    10.1.3 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
    10.1.4 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
    10.1.5 North America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
    10.1.6 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
    10.1.6.1 United States Macular Degeneration Treatment Market
    10.1.6.1.1 United States Macular Degeneration Treatment Market by Disease Indication
    10.1.6.1.2 United States Macular Degeneration Treatment Market by Drug Class
    10.1.6.1.3 United States Macular Degeneration Treatment Market by End User
    10.1.6.2 Canada Macular Degeneration Treatment Market
    10.1.6.2.1 Canada Macular Degeneration Treatment Market by Disease Indication
    10.1.6.2.2 Canada Macular Degeneration Treatment Market by Drug Class
    10.1.6.2.3 Canada Macular Degeneration Treatment Market by End User
    10.1.6.3 Mexico Macular Degeneration Treatment Market
    10.1.6.3.1 Mexico Macular Degeneration Treatment Market by Disease Indication
    10.1.6.3.2 Mexico Macular Degeneration Treatment Market by Drug Class
    10.1.6.3.3 Mexico Macular Degeneration Treatment Market by End User
    10.1.6.4 US Macular Degeneration Treatment Market
    10.1.6.4.1 US Macular Degeneration Treatment Market by Disease Indication
    10.1.6.4.2 US Macular Degeneration Treatment Market by Drug Class
    10.1.6.4.3 US Macular Degeneration Treatment Market by End User
    10.2. EUROPE
    10.2.1 Europe Macular Degeneration Treatment Market Overview
    10.2.2 Europe Macular Degeneration Treatment Market Forecasts and Analysis
    10.2.3 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
    10.2.4 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
    10.2.5 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By End User
    10.2.6 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
    10.2.6.1 Germany Macular Degeneration Treatment Market
    10.2.6.1.1 Germany Macular Degeneration Treatment Market by Disease Indication
    10.2.6.1.2 Germany Macular Degeneration Treatment Market by Drug Class
    10.2.6.1.3 Germany Macular Degeneration Treatment Market by End User
    10.2.6.2 France Macular Degeneration Treatment Market
    10.2.6.2.1 France Macular Degeneration Treatment Market by Disease Indication
    10.2.6.2.2 France Macular Degeneration Treatment Market by Drug Class
    10.2.6.2.3 France Macular Degeneration Treatment Market by End User
    10.2.6.3 Italy Macular Degeneration Treatment Market
    10.2.6.3.1 Italy Macular Degeneration Treatment Market by Disease Indication
    10.2.6.3.2 Italy Macular Degeneration Treatment Market by Drug Class
    10.2.6.3.3 Italy Macular Degeneration Treatment Market by End User
    10.2.6.4 Spain Macular Degeneration Treatment Market
    10.2.6.4.1 Spain Macular Degeneration Treatment Market by Disease Indication
    10.2.6.4.2 Spain Macular Degeneration Treatment Market by Drug Class
    10.2.6.4.3 Spain Macular Degeneration Treatment Market by End User
    10.2.6.5 United Kingdom Macular Degeneration Treatment Market
    10.2.6.5.1 United Kingdom Macular Degeneration Treatment Market by Disease Indication
    10.2.6.5.2 United Kingdom Macular Degeneration Treatment Market by Drug Class
    10.2.6.5.3 United Kingdom Macular Degeneration Treatment Market by End User
    10.3. ASIA-PACIFIC
    10.3.1 Asia-Pacific Macular Degeneration Treatment Market Overview
    10.3.2 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis
    10.3.3 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
    10.3.4 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
    10.3.5 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By End User
    10.3.6 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
    10.3.6.1 Australia Macular Degeneration Treatment Market
    10.3.6.1.1 Australia Macular Degeneration Treatment Market by Disease Indication
    10.3.6.1.2 Australia Macular Degeneration Treatment Market by Drug Class
    10.3.6.1.3 Australia Macular Degeneration Treatment Market by End User
    10.3.6.2 China Macular Degeneration Treatment Market
    10.3.6.2.1 China Macular Degeneration Treatment Market by Disease Indication
    10.3.6.2.2 China Macular Degeneration Treatment Market by Drug Class
    10.3.6.2.3 China Macular Degeneration Treatment Market by End User
    10.3.6.3 India Macular Degeneration Treatment Market
    10.3.6.3.1 India Macular Degeneration Treatment Market by Disease Indication
    10.3.6.3.2 India Macular Degeneration Treatment Market by Drug Class
    10.3.6.3.3 India Macular Degeneration Treatment Market by End User
    10.3.6.4 Japan Macular Degeneration Treatment Market
    10.3.6.4.1 Japan Macular Degeneration Treatment Market by Disease Indication
    10.3.6.4.2 Japan Macular Degeneration Treatment Market by Drug Class
    10.3.6.4.3 Japan Macular Degeneration Treatment Market by End User
    10.4. MIDDLE EAST AND AFRICA
    10.4.1 Middle East and Africa Macular Degeneration Treatment Market Overview
    10.4.2 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis
    10.4.3 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
    10.4.4 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
    10.4.5 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By End User
    10.4.6 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
    10.4.6.1 South Africa Macular Degeneration Treatment Market
    10.4.6.1.1 South Africa Macular Degeneration Treatment Market by Disease Indication
    10.4.6.1.2 South Africa Macular Degeneration Treatment Market by Drug Class
    10.4.6.1.3 South Africa Macular Degeneration Treatment Market by End User
    10.4.6.2 Saudi Arabia Macular Degeneration Treatment Market
    10.4.6.2.1 Saudi Arabia Macular Degeneration Treatment Market by Disease Indication
    10.4.6.2.2 Saudi Arabia Macular Degeneration Treatment Market by Drug Class
    10.4.6.2.3 Saudi Arabia Macular Degeneration Treatment Market by End User
    10.4.6.3 U.A.E Macular Degeneration Treatment Market
    10.4.6.3.1 U.A.E Macular Degeneration Treatment Market by Disease Indication
    10.4.6.3.2 U.A.E Macular Degeneration Treatment Market by Drug Class
    10.4.6.3.3 U.A.E Macular Degeneration Treatment Market by End User
    10.5. SOUTH AND CENTRAL AMERICA
    10.5.1 South and Central America Macular Degeneration Treatment Market Overview
    10.5.2 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis
    10.5.3 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
    10.5.4 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
    10.5.5 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
    10.5.6 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
    10.5.6.1 Brazil Macular Degeneration Treatment Market
    10.5.6.1.1 Brazil Macular Degeneration Treatment Market by Disease Indication
    10.5.6.1.2 Brazil Macular Degeneration Treatment Market by Drug Class
    10.5.6.1.3 Brazil Macular Degeneration Treatment Market by End User
    10.5.6.2 Argentina Macular Degeneration Treatment Market
    10.5.6.2.1 Argentina Macular Degeneration Treatment Market by Disease Indication
    10.5.6.2.2 Argentina Macular Degeneration Treatment Market by Drug Class
    10.5.6.2.3 Argentina Macular Degeneration Treatment Market by End User
    11. INDUSTRY LANDSCAPE
    11.1. MERGERS AND ACQUISITIONS
    11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    11.3. NEW PRODUCT LAUNCHES
    11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
    12. MACULAR DEGENERATION TREATMENT MARKET, KEY COMPANY PROFILES
    12.1. GLAXOSMITHKLINE PLC
    12.1.1. Key Facts
    12.1.2. Business Description
    12.1.3. Products and Services
    12.1.4. Financial Overview
    12.1.5. SWOT Analysis
    12.1.6. Key Developments
    12.2. NOVARTIS AG
    12.2.1. Key Facts
    12.2.2. Business Description
    12.2.3. Products and Services
    12.2.4. Financial Overview
    12.2.5. SWOT Analysis
    12.2.6. Key Developments
    12.3. BAYER AG
    12.3.1. Key Facts
    12.3.2. Business Description
    12.3.3. Products and Services
    12.3.4. Financial Overview
    12.3.5. SWOT Analysis
    12.3.6. Key Developments
    12.4. NEUROTECH PHARMACEUTICALS, INC
    12.4.1. Key Facts
    12.4.2. Business Description
    12.4.3. Products and Services
    12.4.4. Financial Overview
    12.4.5. SWOT Analysis
    12.4.6. Key Developments
    12.5. OPHTHOTECH CORPORATION
    12.5.1. Key Facts
    12.5.2. Business Description
    12.5.3. Products and Services
    12.5.4. Financial Overview
    12.5.5. SWOT Analysis
    12.5.6. Key Developments
    12.6. F. HOFFMANN-LA ROCHE LTD
    12.6.1. Key Facts
    12.6.2. Business Description
    12.6.3. Products and Services
    12.6.4. Financial Overview
    12.6.5. SWOT Analysis
    12.6.6. Key Developments
    12.7. STEMCELLS INC
    12.7.1. Key Facts
    12.7.2. Business Description
    12.7.3. Products and Services
    12.7.4. Financial Overview
    12.7.5. SWOT Analysis
    12.7.6. Key Developments
    12.8. PFIZER, INC
    12.8.1. Key Facts
    12.8.2. Business Description
    12.8.3. Products and Services
    12.8.4. Financial Overview
    12.8.5. SWOT Analysis
    12.8.6. Key Developments
    12.9. SANOFI
    12.9.1. Key Facts
    12.9.2. Business Description
    12.9.3. Products and Services
    12.9.4. Financial Overview
    12.9.5. SWOT Analysis
    12.9.6. Key Developments
    12.10. SANTEN PHARMACEUTICALS
    12.10.1. Key Facts
    12.10.2. Business Description
    12.10.3. Products and Services
    12.10.4. Financial Overview
    12.10.5. SWOT Analysis
    12.10.6. Key Developments
    13. APPENDIX
    13.1. ABOUT THE INSIGHT PARTNERS
    13.2. GLOSSARY OF TERMS
    The List of Companies

    - GlaxoSmithKline plc
    - Novartis AG
    - Bayer AG
    - Neurotech Pharmaceuticals, Inc
    - Ophthotech Corporation
    - F. Hoffmann-La Roche Ltd
    - StemCells Inc
    - Pfizer, Inc
    - Sanofi
    - Santen Pharmaceuticals
    TIPRE00004433
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550
        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount